Newswise PLYMOUTH MEETING, PA [January 10, 2022] The National Comprehensive Cancer Network (NCCN) today announced the publication of new NCCN Guidelines for Patients: Graft-Versus-Host Disease (GVHD). GVHD is a complication that occurs after a donor stem cell or bone marrow (a.k.a. hematopoietic) transplantwhich is used to cure some types of blood cancers. One goal of donor hematopoietic cell transplants is for the donors immune cells to attack the cancerous cells, an important contributor to achieving a cure. When GVHD occurs, the transplanted donor cells attack the patients healthy body tissues, causing mild or severe symptoms. Incidences of acute and chronic GVHD continue to be significant in the United States, in particular with the increasing use of incompletely-matched donorsmeaning the healthy cells are donated from a someone who is not a perfect tissue-type (also known as HLA) match.
GVHD is a transplant complication that comes as a surprise for many patients, said Susan Stewart, Executive Director, BMT InfoNet and 32-year bone marrow transplant survivor. It can significantly impact a patients quality of life, particularly if it persists long-term. Knowing the symptoms, so that it can be caught earlyas well as potential treatment optionsis crucial for GVHD patients.
Anyone who undergoes stem cell transplantation from a donor should be aware of the possibility of acute or chronic GVHD, which arises when the donor immune cells see host tissues as foreign, and attack them, said Ayman A. Saad, MD, Professor of Internal Medicine, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Chair of the NCCN Guidelines Panel for Hematopoietic Cell Transplantation. The symptoms can be very tricky and manifest suddenly, in unusual ways, sometimes years after the transplant. The NCCN Guidelines for Patients: GVHD clearly explains this complicated process and hopefully helps people understand the variety of therapies that can be used to treat it.
The most important piece of advice is to take GVHD seriously, but not panic, said Alison W. Loren, MD, MSCE, Director, Blood & Marrow Transplant, Cell Therapy & Transplant Program, Abramson Cancer Center of the University of Pennsylvania, Vice-Chair of the NCCN Guidelines Panel for Hematopoietic Cell Transplantation. GVHD is very common yet poorly understood, even by physicians. Hopefully, this book brings some order to the chaos by sharing evidence and uniformity. Treatment guidelines, if used effectively, will limit the severity and duration of people suffering from GVHD.
Drs. Saad and Loren stressed the importance of transplant recipients talking to their doctor about anything that feels different after the procedure, even years later, especially issues including:
GVHD can be life-threatening in rare situations, but certainly can impact quality of life. GVHD may be reversible when addressed early. For years, the main treatment was steroids but recent clinical trials have led to new standards of care. Ongoing research will hopefully further improve techniques for both prevention and cure.
NCCN believes that the best management of any patient with cancer is a clinical trial, said Dr. Loren. Some trials require that patients havent received any previous treatment, so its important to bring it up right away and not miss the opportunity for the best possible care while also adding to our knowledge about how the immune system works.
NCCN Guidelines for Patients empower patients and caregivers with an easy-to-read version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)the recognized standard for clinical direction and policy in cancer care. NCCN Guidelines for Patients feature charts, images, and a glossary of medical termsand include suggested questions to ask the doctor.
NCCN Guidelines for Patients: GVHD are available for free online at NCCN.org/patientguidelines and via the NCCN Patient Guides for Cancer App, thanks to funding from the NCCN Foundation. The growing library of NCCN Guidelines for Patients includes more than 60 frequently-updated books for patients and caregivers covering most major types of cancer, including most types of leukemia and lymphoma. There are additional guides covering cancer-related distress, nausea and vomiting, and survivorship (both healthy living & cancer-related late and long-term effects), plus special considerations for adolescents and young adults across all cancer types.
Learn more and help support these and other resources for people with cancer and their caregivers at NCCN.org/foundation.
# # #
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information and follow NCCN on Facebook @NCCNorg, Instagram @NCCNorg, and Twitter @NCCN.
About the NCCN Foundation
The NCCN Foundationwas founded by the National Comprehensive Cancer Network(NCCN) to empower people with cancer and advance oncology innovation. The NCCN Foundation empowers people with cancer and their caregivers by delivering unbiased expert guidance from the worlds leading cancer experts through the library of NCCN Guidelines for Patientsand other patient education resources. The NCCN Foundation is also committed to advancing cancer treatment by funding the nations promising young investigators at the forefront of cancer research. For more information about the NCCN Foundation, visitNCCN.org/foundation.
 Arai S, Arora M, Wang T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015 Feb;21(2):266-74. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25445023.
See the article here:
- Registration is open for the ISSCR 2022 Annual Meeting 15-18 June - EurekAlert - January 13th, 2022
- Stem cell: UC's odd 'unmention' in its top 10 research tales - Capitol Weekly - January 13th, 2022
- Bone Marrow-Derived Stem Cells (BMSCS) Market Size Is Expected To Generate Huge Revenue and Competitive Outlook Industrial IT - Industrial IT - January 13th, 2022
- Outsmarting Cancer: Next Generation Therapies - BioSpace - January 13th, 2022
- Doctors and Researchers Probe How COVID-19 Attacks the Heart - The Scientist - January 13th, 2022
- Legendary Bayer is Reinventing its Story with Cell and Gene Therapy - BioSpace - January 13th, 2022
- Rising Focus on Exploring Potential of Stem Cells as Therapeutic Tools in Drug Targeting and Regenerative Medicine to Fuel Revenue Growth of Stem... - January 11th, 2022
- Stem Cell Media Market Statistics Based on Facts and Figures, 2022 to 2031 - Taiwan News - January 11th, 2022
- Regenerative Medicine: Innovation & Innovators leading online scientific event by IASRM in this pandemic - ThePrint - January 11th, 2022
- JPM22: Pfizer's big bet on mRNA, Biogen 'proven wrong' on Aduhelm price and the next cell therapies - BioPharma Dive - January 11th, 2022
- Severe Combined Immunodeficiency Treatment Market: Availability of Drugs and Immune-related Treatments Are Anticipated to Drive the Global Market -... - January 11th, 2022
- Peter Dirks, Asthma and Physics - Brain Tumour Research - January 9th, 2022
- Overview - Brain Tumor Stem Cell Research Lab - Mayo ... - January 7th, 2022
- Religious Groups Official Positions on Stem Cell Research ... - January 7th, 2022
- EBMT trial demonstrates improvements in immunosuppressive treatment of patients with Severe Aplastic Anemia - EurekAlert - January 7th, 2022
- CMML vs. CML: What's the Difference? - Healthline - January 7th, 2022
- Effects of Stem Cell Therapy on Diabetic Mellitus Erectile Dysfunction: A Systematic Review and Meta-analysis - Newswise - January 5th, 2022
- Researchers Awarded Grant to Study New Method of Islet Transplantation - Weill Cornell Medicine Newsroom - January 5th, 2022
- FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir's Posoleucel for the Treatment of Adenovirus (AdV) Infections in... - January 5th, 2022
- Jake's mice: Searching for answers to the puzzle of autism - huntingdondailynews.com - January 5th, 2022
- Freeze Thaw Chambers Market: The cryopreserved products segment is expected to drive the growth of the market - BioSpace - January 5th, 2022
- Gait Rehabilitation System Market: Rising incidence of various neurological disorders to drive the market - BioSpace - January 5th, 2022
- Worldwide Translational Regenerative Medicine Industry to 2026 - Ongoing Research in Organ Transplantation With Regenerative Medicine Presents... - January 5th, 2022
- These 2021 Biotech Breakthroughs Will Shape the Future of Health and Medicine - Singularity Hub - January 5th, 2022
- LifeBank Chain Announces Upcoming Gene and Cell Collaboration Platform With Disrupt Blockchain Technologies - Yahoo Finance - January 2nd, 2022
- Dental mesenchymal stromal/stem cells in different microenvironments implications in regenerative therapy - Newswise - January 2nd, 2022
- Bristol Myers Squibb exec on the companys growth in Seattle and beating cancer with immune cells - GeekWire - January 2nd, 2022
- Postdoc Position in Bioinformatics in Stem Cell Neurobiology job with MASARYK UNIVERSITY | 276195 - Times Higher Education (THE) - December 25th, 2021
- USC Stem Cell - December 25th, 2021
- Communication between cells plays a major role in deciding their fate - EurekAlert - December 25th, 2021
- Researchers uncover new details behind inflammation that promotes heart disease - EurekAlert - December 25th, 2021
- Epithelial Cell Culture Media Market to hit US$ 303040.33 thousand by 2028, at 11.4% CAGR: The Insight Partners - Digital Journal - December 25th, 2021
- Global Regenerative Medicine Market is Expected to Reach USD 57.08 Billion by 2027, Growing at a CAGR of 11.27% Over the Forecast Period. -... - December 23rd, 2021
- Communication between cells plays a major role in deciding their fate > News > USC Dornsife - USC Dornsife College of Letters, Arts and Sciences - December 23rd, 2021
- Emendo Biotherapeutics and Seattle Childrens Research Institute Announce Collaboration to Develop CRISPR-based Therapeutic Strategy for Severe... - December 23rd, 2021
- The 10 Most Compelling Research Stories of 2021 PharmaLive - PharmaLive - December 23rd, 2021
- UTSW working to reprogram cells to strengthen immunity in geriatric patients - EurekAlert - December 23rd, 2021
- Cell Proliferation Kit Market Objectives of the Study Includes Research Methodology and Assumptions and Forecast by 2031 - Digital Journal - December 23rd, 2021
- Drexel Researchers Develop and Employ Cell-Based Approach to Studying Mechanisms of Gulf War Illness - Drexel News Blog - December 21st, 2021
- This Startup Is Makingand ProgrammingHuman Cells - WIRED - December 21st, 2021
- Amniotics joins Vinnova funded 'CAMP' to improve outcome of lung transplantations with PulmoStem - marketscreener.com - December 21st, 2021
- COVID-19: Are T cell vaccines the future? - Medical News Today - December 21st, 2021
- The 10 Most Compelling Research Stories of 2021 - BioSpace - December 21st, 2021
- SpaceX CRS-24 launching multiple life science investigations to the International Space Station - EurekAlert - December 21st, 2021
- Fast food: Israeli team stumbles upon speed boost for slow-growing cultured meat - The Times of Israel - December 21st, 2021
- MRC Lead Apologizes Following Bullying Allegations - The Scientist - December 21st, 2021
- End of Year Wrap Up: Key Updates in Myeloma in 2021 and Possible Upcoming FDA Updates - Cancer Network - December 21st, 2021
- City of Hope presents leading-edge research on blood cancer therapies and its vaccine to reduce stem cell transplant complications at American Society... - December 17th, 2021
- IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing... - December 17th, 2021
- Century Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology ... - The Bakersfield Californian - December 17th, 2021
- Outlook on the Cell Isolation Global Market to 2026 - by Technique, Cell Type, Product, Application, End-use and Region - ResearchAndMarkets.com -... - December 17th, 2021
- CAR T-cell Therapy Found Equivalent to Standard of Care as Second-line Treatment for Aggressive non-Hodgkin Lymphoma - PRNewswire - December 15th, 2021
- Novel CD19-Directed CAR T-Cell Therapy Shows Favorable Results in R/R DLBCL - Targeted Oncology - December 15th, 2021
- Global CRISPR Technology Market Research Report 2021: Focus on Design Tools, Plasmid and Vector, Cas9 and G-RNA, & Delivery System Products -... - December 15th, 2021
- Building an entrepreneurial ecosystem is about a lot more than education and science funding - American Enterprise Institute - December 15th, 2021
- Q&A: Dr. Thomas Rando on preventing age-related diseases and turning discoveries into cures - UCLA Newsroom - December 12th, 2021
- Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology... - December 12th, 2021
- Ten Problems with Embryonic Stem Cell Research | The ... - December 11th, 2021
- New stem cell identified for lung tissue regeneration ... - December 11th, 2021
- Harvard Department of Stem Cell and Regenerative Biology ... - December 11th, 2021
- Stem Cells Australia | Australian research, stem cell ... - December 11th, 2021
- Research Assistant Stem Cell Project Job at The Florey Institute in Melbourne, Australia - The Conversation AU - December 11th, 2021
- Ethical issues cloud case report of unproven stem cell therapy for autism - Spectrum - December 11th, 2021
- Mesenchymal Stem Cells Market Size 2021 Emerging Technologies, Global Regions with Industry Share Analysis, Gross Margin, Regional Demand and Forecast... - December 11th, 2021
- For children, young adults with recurrent AML, immunotherapy shows promise Washington University School of Medicine in St. Louis - Washington... - December 11th, 2021
- UEA researchers reveal how immune cells use the bodys fat stores to fight infection - News-Medical.net - December 11th, 2021
- Sanford Health opens study of cell injections for arthritis - Sanford Health News - December 11th, 2021
- Cell types outside the pancreas make insulin, too, study shows - Yale News - December 11th, 2021
- Doctoral Student Finds Alternative Cell Option For Organs-On-Chips - Texas A&M University Today - December 11th, 2021
- Caring Cross Announces Publication in Nature Communications Demonstrating Effectiveness of Place-of-Care Manufacture of Anti-CD19 CAR T Cells for... - December 11th, 2021
- Stem cells and the future of health care - The Globe and Mail - December 9th, 2021
- How the body uses fat to fight infection - EurekAlert - December 9th, 2021
- The Ethics of Human Cloning and Stem Cell Research ... - December 7th, 2021
- An Overview of Stem Cell Research | The Center for ... - December 7th, 2021
- Global Research Antibodies Outlook to 2028: Rise in R&D Initiatives and an Increase in Neurobiology and Stem Cell Research are Key Factors in Market... - December 7th, 2021
- University of Michigan Stem Cell Research | Frequently ... - November 30th, 2021
- Postdoctoral Research Associate in Centre for Stem Cells and Regenerative Medicine job with KINGS COLLEGE LONDON | 273388 - Times Higher Education... - November 30th, 2021
- Stem cell therapy potentially could treat Type 1 diabetes by helping patients produce insulin - USA TODAY - November 30th, 2021
- UCLA Broad Stem Cell Research Center receives $5 million ... - November 30th, 2021
- ReproCELL Incorporated : Everything you need to know about the REPROCELL iPSC Biobank - marketscreener.com - November 30th, 2021